Table 5

Impact of TNFi treatment on radiographic progression in male versus female axSpA patients

OR95% CIP valueOR95% CIP value
TNFi use prior to X-ray interval0.530.31 to 0.900.021.010.31 to 3.230.99
mSASSS at start of X-ray interval1.051.03 to 1.08<0.0011.141.07 to 1.20<0.001
Length of the X-ray interval (+1 year)1.910.91 to 3.980.093.370.91 to 12.40.07
Age (+1 year)1.061.02 to 1.100.0011.020.96 to 1.080.54
Symptom duration (+5 years)0.950.78 to 1.160.611.060.73 to 1.550.76
No of exercise sessions/week0.950.85 to 1.060.340.890.66 to 1.190.42
  • Results from different multivariable models with spinal radiographic progression defined as an increase of ≥2 mSASSS units in 2 years and multiple imputation of missing covariate data. Analyses performed in 463 radiographic intervals from 317 male patients (88 events) and 261 intervals from 188 female patients (20 events) in axSpA.

  • axSpA, axial spondyloarthritis; mSASSS, Modified Stoke Ankylosing Spondylitis Spinal Score; TNFi, tumour necrosis factor inhibitor.